Business
Magic Mushroom-Based Therapy for Depression Shows Promise
A mock patient in trial site therapy room. Source: Compass Pathways PlcBy and
November 9, 2021, 5:00 AM MST Updated on November 9, 2021, 5:24 AM MST
- Effects seen day after taking mushroom-like drug, CEO says
- Some patients showed suicidal and self-harming behaviors
Compass Pathways Plc’s experimental therapy based on psilocybin, or so-called magic mushrooms, showed promise in a midstage clinical trial in patients whose depression didn’t improve from other treatments.
Nearly a quarter of the people treated with the highest dose of Compass Pathways’ drug candidate, called COMP360, saw the severity of their depression reduced after three months, as measured on a scale used by psychiatrists. COMP360 is a patented formulation of the active ingredient in psychedelic mushrooms.
No comments:
Post a Comment